Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $103.4 million.

  • Coherus Oncology's Cash & Equivalents rose 579.59% to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 579.59%. This contributed to the annual value of $126.0 million for FY2024, which is 2244.71% up from last year.
  • Coherus Oncology's Cash & Equivalents amounted to $103.4 million in Q3 2025, which was up 579.59% from $216.9 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Cash & Equivalents peaked at $417.2 million during Q4 2021, and registered a low of $16.1 million during Q1 2023.
  • In the last 5 years, Coherus Oncology's Cash & Equivalents had a median value of $159.2 million in 2024 and averaged $191.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 9504.27% in 2023, then soared by 150901.21% in 2024.
  • Over the past 5 years, Coherus Oncology's Cash & Equivalents (Quarter) stood at $417.2 million in 2021, then plummeted by 84.77% to $63.5 million in 2022, then surged by 61.91% to $102.9 million in 2023, then grew by 22.45% to $126.0 million in 2024, then decreased by 17.97% to $103.4 million in 2025.
  • Its Cash & Equivalents was $103.4 million in Q3 2025, compared to $216.9 million in Q2 2025 and $82.4 million in Q1 2025.